On Sunday, Summit Therapeutics said the FDA had rejected ivonescimab for a hard-to-treat kind of lung cancer. China's Akeso built the drug and has sold it in China since 2024. It blocks two things at once: a signal tumors use to hide from the immune system, and one they use to grow blood vessels. Summit tested it with chemo in 438 patients whose lung cancer had kept growing after targeted pills. A gene change called an EGFR mutation drives their cancer. Patients on the drug went about 6.8 months before their cancer worsened, versus 4.4 months on chemo alone. But the survival result just missed the bar for statistical proof. The FDA said that wasn't enough. It would have been the first drug of its kind approved in the US.

The FDA Was Right to Ask for Longer Lives

This camp says slowing a tumor isn't the same as helping people live, and the agency warned Summit early.

Slowing the cancer wasn't enough without proof patients lived longer. Summit says the FDA's letter told the company it hadn't shown "substantial evidence of effectiveness" without a clear survival gain. It also said the slower cancer growth alone "does not support a positive benefit-risk profile." Patients on the drug lived a median 16.8 months, versus 14.0 months on chemo alone. That gap fell short of statistical proof.

This rejection didn't come out of nowhere. In May 2025, Summit said the FDA had told it a statistically significant survival benefit was "necessary" for approval. That same month, Leerink Partners analyst Daina Graybosch wrote that the FDA's "high bar for demonstrated overall survival benefit make approval less likely." STAT's Adam Feuerstein called Sunday's rejection "not entirely unforeseen."

A leading lung cancer doctor wasn't impressed either. Dr. Suresh Ramalingam runs Emory's Winship Cancer Institute, and he reviewed the trial at a major lung cancer meeting in September 2025. "Regardless of the strategy, the PFS is relatively modest," he said, referring to the time before the cancer worsens. He also said he saw "no clear evidence" that the part of the drug aimed at the immune system was doing the work.

The trial had little data on Western patients at first. At the main analysis, the trial had followed them for a median of only 9.2 months, and they showed no survival gain.

Patients Lost a Real Option

This camp says people out of good choices deserved this drug, and the newer data suggest it helps.

These patients are running out of choices. Summit says no FDA-approved treatment has clearly extended survival for patients like these. Ramalingam made a similar point: "We have very limited options for these patients aside from platinum-based chemotherapy." Co-CEO Dr. Maky Zanganeh, a cancer survivor, said in Sunday's statement that "every additional treatment option matters." Chairman and co-CEO Robert Duggan said the company is "disappointed for patients and their families." Still, patients do have other approved drugs, including Johnson & Johnson's Rybrevant and AstraZeneca's Tagrisso.

Newer data hint that patients on the drug live longer. Summit says later data showed a 24% lower risk of death, and the result was the same for Asian and Western patients. Those were extra analyses done after the main one, so they don't count as formal proof. Dr. Jonathan Goldman, the UCLA oncologist who presented the trial, called the slowdown in cancer growth "clinically meaningful."

Some analysts saw a strong answer to one big worry. In July, Stifel analysts called the new results "a strong counter" to fears that Chinese data wouldn't hold up in Western patients. They said the update "reduces an already-limited" regulatory risk, meaning the chance the FDA would say no.

This Is One Narrow Loss, and the Bigger Test Is Still Coming

This camp says the rejection covers one small use, and the drug's biggest test is a head-to-head trial against Keytruda.

This no covers only one small group of lung cancer patients. Endpoints News called it a "narrow lung cancer setting." Duggan said that "nothing changes" about Summit's belief in ivonescimab. He pointed to "five positive Phase III studies" between Summit and Akeso. Summit's statement didn't say what it will do next for this group of patients.

Beating Keytruda would matter far more. Mizuho analyst Graig Suvannavejh had called ivonescimab "the next major backbone" of cancer treatment. Analysts expect drugs like it to be a $30 billion market by 2032. Summit is testing the drug against Merck's Keytruda in a big trial in newly diagnosed lung cancer. Summit expects the first results by year-end.

Rival drugmakers aren't far behind. Pfizer, Merck and AbbVie are testing drugs that work the same way. So are BioNTech and Bristol Myers Squibb, working together.

Where This Lands

Summit says the FDA rejected the drug because the trial didn't prove patients live longer, and that the agency warned it in 2025. Summit says its newer data show a survival benefit, and that no approved treatment has proven one for these patients. Endpoints News calls the rejection a narrow one. The drug's next big test is the Keytruda trial. Summit expects the first results from that trial by year-end.

Sources